[Skip to Content]
[Skip to Content Landing]

September 2019 - April 2015

Decade

Year

Issue

December 2017, Vol 3, No. 12, Pages 1599-1751

Original Investigation

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis

Abstract Full Text
free access has active quiz
JAMA Oncol. 2017;3(12):1634-1639. doi:10.1001/jamaoncol.2017.1968

This meta-analysis assesses the clinical utility of whole-body magnetic resonance imaging in 13 cohorts of germline TP53 mutation carriers.

Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort

Abstract Full Text
free access has audio
JAMA Oncol. 2017;3(12):1640-1645. doi:10.1001/jamaoncol.2017.1350

This cohort study evaluates baseline surveillance methods for cancer detection in patients with Li-Fraumeni syndrome.

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women

Abstract Full Text
free access has audio
JAMA Oncol. 2017;3(12):1647-1653. doi:10.1001/jamaoncol.2017.1996

This cohort study uses genomic DNA from the New York Breast Cancer Study to determine the frequency of cancer-predisposing mutations other than the BRCA1 and BRCA2 founder alleles among patients of Ashkenazi Jewish ancestry with breast cancer.

Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1654-1662. doi:10.1001/jamaoncol.2017.0595

This cohort study from The Cancer Genome Atlas investigates racial differences in breast cancer molecular features and survival and estimates the heritability of breast cancer subtypes.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1663-1672. doi:10.1001/jamaoncol.2017.0751

This study identifies prostate cancer subtypes based on luminal and basal lineage and assesses the association of those subtypes with clinical outcomes and response to treatment.

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

Abstract Full Text
open access
JAMA Oncol. 2017;3(12):1675-1682. doi:10.1001/jamaoncol.2017.2714

This cohort study examines the prognostic association of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia and a risk-stratifying composite model that incorporates comorbidities, age, and cytogenetic/molecular risks.

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015

Abstract Full Text
open access
JAMA Oncol. 2017;3(12):1683-1691. doi:10.1001/jamaoncol.2017.3055

This data analysis of the Global Burden of Disease 2015 study on primary liver cancer reports incidence, mortality, and disability-adjusted life-years for 195 countries or territories from 1990 to 2015, and presents global, regional, and national estimates on the burden of liver cancer.

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1692-1696. doi:10.1001/jamaoncol.2017.2797

This comparative clinical study discusses problems with conventional trial design and analysis and presents alternatives to the hazard ratio using a recent immunotherapy study as an illustrative example.

Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study

Abstract Full Text
free access online only
JAMA Oncol. 2017;3(12):e172319. doi:10.1001/jamaoncol.2017.2319

This cohort study of patients with early-stage colorectal cancer examines whether prediagnostic systemic inflammation is associated with at-diagnosis sarcopenia and explores whether these factors interact to predict cancer survival.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Abstract Full Text
free access online only
JAMA Oncol. 2017;3(12):e173290. doi:10.1001/jamaoncol.2017.3290

This cohort study examines the prognostic role of CD8+ T lymphocytes for survival among women with epithelial ovarian cancer.

Brief Report

Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1697-1701. doi:10.1001/jamaoncol.2017.0769

This population-based study evaluates the risk of cancer in families who are positive for Amsterdam criteria for Lynch syndrome.

Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies

Abstract Full Text
open access
JAMA Oncol. 2017;3(12):1702-1706. doi:10.1001/jamaoncol.2017.0619

In this cohort study of patients with Lynch syndrome with colorectal, endometrial, and/or ovarian cancer, mutation genes and types are evaluated for their association with age at cancer onset.

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1707-1711. doi:10.1001/jamaoncol.2017.2140

This study examines the association between genomic metrics and the extent of immune infiltration in triple-negative breast cancers.

Research Letter

Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1733-1734. doi:10.1001/jamaoncol.2017.1346

This cohort study of patients with Li-Fraumeni syndrome assesses the diagnostic yield and false-positive rate of an annual surveillance program including whole-body magnetic resonance imaging in patients identified as carriers of TP53 gene mutations.

Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1735-1736. doi:10.1001/jamaoncol.2017.1355

This prospective study of surveillance strategies uses a whole-body screening program, including whole-body magnetic resonance imaging, in carriers of germline mutations in TP53.

Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1736-1737. doi:10.1001/jamaoncol.2017.1358

This interim analysis of an ongoing randomized clinical trial presents preliminary findings regarding use of whole-body magnetic resonance imaging for cancer surveillance of TP53 mutation carriers.

Review

Using the National Cancer Database for Outcomes Research: A Review

Abstract Full Text
JAMA Oncol. 2017;3(12):1722-1728. doi:10.1001/jamaoncol.2016.6905

This review describes the use of the National Cancer Database to study cancer care, with a focus on the advantages of using the database and important considerations that affect the interpretation of National Cancer Database studies.

JAMA Oncology Diagnostic Test Interpretation

A New Monoclonal Protein Detected in a Patient With Myeloma Undergoing Elotuzumab Therapy

Abstract Full Text
has active quiz
JAMA Oncol. 2017;3(12):1729-1730. doi:10.1001/jamaoncol.2017.2665

This Diagnostic Test Interpretation examines serum protein electrophoresis and free light chain assay results in a patient with myeloma.

Viewpoint

Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer Research

Abstract Full Text
JAMA Oncol. 2017;3(12):1621-1622. doi:10.1001/jamaoncol.2017.1822

This Viewpoint examines several dimensions of conflicts of interest, describes the distinct entity of conflicting interests, and describes how they may affect clinical cancer research.

Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not?

Abstract Full Text
JAMA Oncol. 2017;3(12):1623-1624. doi:10.1001/jamaoncol.2017.0470

This Viewpoint reports that prostate-specific antigen screening should be offered at a young age, and when potentially lethal cancers are more likely to be cured.

Editorial

Adjuvant Ipilimumab for Melanoma—The $1.8 Million per Patient Regimen

Abstract Full Text
JAMA Oncol. 2017;3(12):1628-1629. doi:10.1001/jamaoncol.2017.3123

Death by Gun Violence—A Public Health Crisis

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1630-1631. doi:10.1001/jamaoncol.2017.4357
Invited Commentary

Cancer Screening in Li-Fraumeni Syndrome

Abstract Full Text
JAMA Oncol. 2017;3(12):1645-1646. doi:10.1001/jamaoncol.2017.2459

Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer

Abstract Full Text
JAMA Oncol. 2017;3(12):1673-1674. doi:10.1001/jamaoncol.2017.0750
JAMA Oncology Patient Page

Febrile Neutropenia

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1751. doi:10.1001/jamaoncol.2017.1114
Cancer Care Chronicles

Patients With Lung Cancer Need Love Too

Abstract Full Text
JAMA Oncol. 2017;3(12):1625. doi:10.1001/jamaoncol.2017.2331

The Difficult Transition

Abstract Full Text
JAMA Oncol. 2017;3(12):1626-1627. doi:10.1001/jamaoncol.2017.2669
Poetry and Oncology

The Rest of Them

Abstract Full Text
JAMA Oncol. 2017;3(12):1745. doi:10.1001/jamaoncol.2017.2447
Comment & Response

Overestimating the Benefit of Cancer Drugs

Abstract Full Text
JAMA Oncol. 2017;3(12):1737-1738. doi:10.1001/jamaoncol.2017.0107

Overestimating the Benefit of Cancer Drugs—Reply

Abstract Full Text
JAMA Oncol. 2017;3(12):1738-1739. doi:10.1001/jamaoncol.2017.1976

The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste

Abstract Full Text
JAMA Oncol. 2017;3(12):1739-1740. doi:10.1001/jamaoncol.2017.1750

Telomere Length and Risk of Cancer and Non-neoplastic Diseases: Is Survivin the Ariadne's Thread?

Abstract Full Text
JAMA Oncol. 2017;3(12):1740-1741. doi:10.1001/jamaoncol.2017.2313

The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste—Reply

Abstract Full Text
JAMA Oncol. 2017;3(12):1740. doi:10.1001/jamaoncol.2017.2503

Telomere Length and Risk of Cancer and Non-neoplastic Diseases: Is Survivin the Ariadne's Thread?—Reply

Abstract Full Text
JAMA Oncol. 2017;3(12):1741-1742. doi:10.1001/jamaoncol.2017.2316
Correction

Error in Kaplan-Meier Curves

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1742. doi:10.1001/jamaoncol.2017.4131

Incorrect Hazard Ratio in Figure 2

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1742. doi:10.1001/jamaoncol.2017.4136

Incorrect Percentages in the Abstract

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1742. doi:10.1001/jamaoncol.2017.4368
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1607. doi:10.1001/jamaoncol.2016.4476
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(12):1599. doi:10.1001/jamaoncol.2016.4475
×